We are live on ! Find out more
BCTX icon

BriaCell Therapeutics

19 hedge funds and large institutions have $6.38M invested in BriaCell Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

307% more call options, than puts

Call options by funds: $912K | Put options by funds: $224K

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.87% less ownership

Funds ownership: 15.6% → 13.73% (-1.9%)

17% less funds holding

Funds holding: 23 → 19 (-4)

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

76% less capital inflows, than outflows

Capital inflows: $589K | Capital outflows: $2.41M

Holders
19
Holders Change
-4
Holders Change %
-17.39%
% of All Funds
0.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
2
Increased
7
Reduced
6
Closed
6
Calls
$912​K
Puts
$224​K
Net Calls
+$688​K
Net Calls Change
-⁠$3.67​M

BCTX Hedge Fund Activity: Q1 2024 in Review

19 of the 6,969 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics (BCTX) for Q1 2024, worth a combined $6.38M — down 56% from $14.6M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BCTX and 2 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 7 added.

The largest buyer was Bank of Montreal, adding an estimated $294K. The largest seller was Wasatch Advisors, exiting entirely with an estimated $1.56M sold.

  • 19 institutional investors held BriaCell Therapeutics (BCTX) as of Q1 2024, down from 23 in Q4 2023.
  • Funds reported $6.38M of BriaCell Therapeutics stock for Q1 2024, down 56% quarter-over-quarter.
  • 2 funds opened new BriaCell Therapeutics positions in Q1 2024 and 6 closed out, a net change of -4 holders.
  • The largest BriaCell Therapeutics buyer in Q1 2024 was Bank of Montreal, an estimated $294K added.
  • The largest BriaCell Therapeutics seller in Q1 2024 was Wasatch Advisors, an estimated $1.56M sold.

Based on aggregated 13F filings for Q1 2024.